InflaRx N.V. (IFRX) Dividend History

InflaRx N.V. is a biopharmaceutical company focused on developing and commercializing therapies that target inflammatory diseases. The company's pipeline mainly includes monoclonal antibodies designed to inhibit the complement system's role in inflammatory processes, aiming to treat conditions such as hidradenitis suppurativa and other severe inflammatory disorders. Headquartered in the Netherlands, InflaRx leverages its expertise in immunology to develop innovative treatments for unmet medical needs.

Website: https://www.inflarx.de

Dividend History

InflaRx N.V. currently does not pay dividends

Company News

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

InflaRx announced that the Independent Data Monitoring Committee recommended stopping the Phase 3 trial for vilobelimab in pyoderma gangrenosum due to futility. The company will focus on its oral inhibitor INF904 and consider cost-saving measures.

GlobeNewswire Inc.
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

InflaRx N.V. announced the pricing of its public offering of 8,250,000 ordinary shares and 6,750,000 pre-funded warrants at $2.00 per share. The company intends to use the net proceeds to fund the clinical development of its pipeline candidates and for general corporate purposes.

GlobeNewswire Inc.
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

InflaRx's anti-C5a antibody vilobelimab has received a positive opinion from the CHMP of the EMA for the treatment of SARS-CoV-2-induced ARDS. The positive opinion is based on the results of the PANAMO trial, which showed improved survival with vilobelimab treatment.

GlobeNewswire Inc.
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, as one of three investigational therapies to be assessed in a Phase 2 clinical platform study exploring potential new options for the treatment of acute respiratory distress syndrome (ARDS).

GlobeNewswire Inc.
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held from May 17-22, 2024 in San Diego.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 20:04:56 UTC